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Abstract
Cocoa is a rich source bioactive compounds, i.e., ﬂavan-3-ols, and its consumption has been associated with several beneﬁcial
effects, such as the positive modulation of the hemostasis targeted by the platelet function. However, these phenolic compounds
have a very low bioavailability and extensively undergo phase I and II metabolism, with the appearing into the bloodstream of (epi)
catechin conjugates and phenyl-g-valerolactones and their conjugates, at different times.
The aims of this study were to explore the effect of dark chocolate on platelet function and to investigate the relationship between
this interplay and ﬂavan-3-ol derived metabolites.
Eighteen healthymale volunteers ingested 50g of 90%cocoa chocolatewithin 5minutes. Blood sampleswere collected immediately
before chocolate ingestion (T0) and 4hours afterwards (T1). Platelet function analyzer (PFA)-100 closure time was assessed using
collagen/adenosine-50-diphosphate (COL/ADP) and collagen/epinephrine (COL/EPI) cartridges. Plasma ﬂavan-3-ol metabolites were
identiﬁed and quantiﬁed by means of liquid chromatography coupled to a triple quadrupole mass spectrometer (UHPLC-ESI-MS/MS).
Results evidenced a signiﬁcant increase of COL/ADP-induced PFA-100 closure time, but not COL/EPI, 4hours after ingestion of
dark chocolate. Total plasma structurally-related (epi)catechin metabolite (SREM) concentration signiﬁcantly increased at T1,
together with 4 out of the 6 detected metabolites. Total phenyl-g-valerolactone concentrations remained unchanged. Spearman
correlations evidenced a strong correlation between COL/ADP closure time and SREMs, mainly led by (epi)catechin-sulfate isomers.
These data conﬁrm that the potential beneﬁcial effect of dark chocolate on primary hemostasis may be mediated by ﬂavan-3-ol
circulating metabolites.
Abbreviations: ADME = absorption, distribution, metabolism, and elimination, ADP = adenosine-50-diphosphate, COL/ADP =
collagen/adenosine-50-diphosphate, COL/EPI = collagen/epinephrine, IQR = interquartile range, NO = nitric oxide, PFA = platelet
function analyzer, SPE = solid phase extraction, SREM = structurally-related (epi)catechin metabolite.
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1. Introduction beneﬁts, including improvement of vascular function and bloodReliable evidence exists to suggest that consumption of ﬂavan-3-
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1pressure.[1,2] Cocoa is rich in ﬂavan-3-ols, a class of ﬂavonoids
which includes monomers like ()-epicatechin and (+)-catechin,
and polymers like procyanidins. Monomers are able to cross the
gut epithelium, to be absorbed and to peak into the bloodstream
within 1 or 2hours after ingestion, mainly as glucuronide, sulfate,
or methyl conjugates[3] (hereinafter referred as structurally-
related (epi)catechin metabolites, SREMs). Dimers and oligomers
are poorly absorbed and undergo, as well as monomers, an
intense gut microbiota metabolism, with the generation of lower
molecular weight compounds, such as phenyl-g-valerolac-
tones.[3] These smaller metabolites appear into the bloodstream,
together with their conjugated forms, at later times, namely from
3 to 24hours after food consumption, easily reachingmicromolar
concentrations.[4] For these reasons, there is still a debate
regarding the endorsement of ﬂavan-3-ols and the derived
metabolites as main responsible of the effects of cocoa intake on
primary and secondary hemostasis in healthy subjects.[5–9]
Recent evidence shows that dietary ﬂavan-3-ols may positively
modulate hemostasis, acting through mechanisms that both
directly and indirectly inﬂuence platelet function.[10] Other than
primary hemostasis, platelets play also an important physiologi-
cal role in many atherothrombotic, inﬂammatory, and neoplastic
diseases.[11] Platelets actively interact with leucocytes and
endothelial cells, release procoagulant factors, and also produce
cytokines and chemokines which ultimately interplay with the
immune response.[12] A preliminary intervention study from our
group showed a signiﬁcant inﬂuence of dark chocolate
Montagnana et al. Medicine (2018) 97:49 Medicineconsumption by healthy volunteers on secondary hemostasis, but
it has not been yet fully ascertained which of the compounds may
be correlated to the potential anti-thrombotic effects through
attenuation of the clotting cascade.[13]
Therefore, this study was aimed at investigating the acute
impact of dietary intake of cocoa on primary hemostasis and
determining whether these changes may be associated with
ﬂavan-3-ol circulating metabolites.2. Materials and methods
The study was carried out on 18 healthy men volunteers enrolled
from the laboratory staff (age: 36±10 years; body mass index
(BMI): 22±3kg/m2), who ingested 50g of commercial dark
(90% cocoa) chocolate (Noir Prodigieux, Lindt, Kilchberg,
Switzerland), in a maximum time of 5minutes. The nutritional
characteristics of the 50g of dark chocolate were as follows:
1242kJ (i.e., 296kcal), 27.5g of lipids (15g saturated fat acids),
7g of carbohydrates (3.5g of sugars), 5g of proteins, and 7.5
gallic acid equivalents of polyphenols. Blood was drawn early in
the morning, immediately before chocolate ingestion (T0) and 4
hours afterwards (T1). Volunteers were asked to fast for 8hours
before blood samples collection and to abstain from eating and
drinking any food or beverage except water between the 2
sampling points. Exclusion criteria were BMI >30kg/m2, blood
pressure (BP) >140/90mmHg, allergies to peanut or cocoa,
current intake of dietary supplements, vegan/vegetarian diet.
Blood sampling was carried out by the same expert phlebotomist,
into evacuated blood tubes containing 0.109mol/L K2EDTA or
0.109mol/L buffered sodium citrate (Vacutest Kima, Padova,
Italy). All participants provided an informed consent for
participation to this study, which was carried out in accordance
with the Declaration of Helsinki and was approved by the local
ethical committee (University Hospital of Verona; 971CESC, July
25, 2016).Table 1





Hemoglobin, g/L 154 (136–167)
Red blood cells, 1012/L 5.0 (4.8–5.8)
Mean corpuscular volume, fL 89.3 (84.4–95.4)
Leucocytes, 109/L 5.9 (4.5–8.0)
Platelets, 109/L 243 (158–394)
Total cholesterol, mmol/L 4.8 (3.5–6.8)
Triglycerides, mmol/L 0.9 (0.4–2.6)
Fasting plasma glucose, mmol/L 4.6 (3.6–5.6)
Data are reported as mean± standard deviation or as median (range).
BMI, body mass index.2.1. Laboratory methods
Platelet function (i.e., adhesion and generation of stable
aggregates) was investigated using whole blood collected
immediately before dark chocolate ingestion and 4hours
afterwards, using a Platelet Function Analyzer 100 (PFA-100;
Siemens Healthcare Diagnostics Products; Marburg, Germany
GmbH) instrument. This device alternatively uses equine type I
collagen and epinephrine bitartrate (collagen/epinephrine) and
equine type I collagen and adenosine-50-diphosphate (collagen/
ADP) as agonists.[14] The platelet function event is detected as an
end-point of adhesion, activation and aggregation, and expressed
as a closure time of both collagen/epinephrine and collagen/ADP.
The local reference ranges are 82 to 164seconds and 62 to 116
seconds for collagen/ADP and for collagen/epinephrine, respec-
tively, while the total imprecision values of both assay
components are 5.5% and 4.3% for collagen/epinephrine and
for collagen/ADP, respectively.[15]
Concerning circulating polyphenols assessment, plasma sam-
ples of all volunteers were extracted using a solid phase extraction
(SPE) method, as reported elsewhere.[4] Flavan-3-ol metabolites
were measured in extracted plasma samples by a UHPLC
DIONEX Ultimate 3000 equipped with a triple quadrupole TSQ
Vantage mass spectrometer (Thermo Fisher Scientiﬁc Inc., San
José, CA) ﬁtted with a heated-ESI (H-ESI) (Thermo Fisher
Scientiﬁc Inc., San José, CA) probe. Chromatographic separation
and ionization parameters were set as previously reported.[16]2Quantiﬁcation was performed with calibration curves of stand-
ards, when available. When not available, the conjugated
metabolites were quantiﬁed with the most structurally similar
compound. Phenyl-g-valerolactone conjugates were synthesized
in house.[16]2.2. Statistics
The Kolmogorov–Smirnov test was used to test normality of
distribution for all variables. Signiﬁcance of differences between
T0 and T1 was tested with paired Wilcoxon signed-rank test and
the correlation between values was assessed with Spearman test.
All values are reported as median± interquartile range (IQR) and
the reported P values are 2-tailed, with a P value <.05 indicating
statistical signiﬁcance. Statistical analyses were performed with
IBM SPSS 25.0 Statistics (IBM SPSS, Inc., Chicago, IL).3. Results
A total of 13 phenolic compounds were identiﬁed and quantiﬁed
in plasma samples of healthy men volunteers (Table 1). The
retention times and spectrometric characteristics of the detected
compounds are reported in Table 2. A signiﬁcant increase in the
sum of SREMs was observed at T1 compared with T0 (1.99±
0.90mmol/L vs 0.99±1.57, P= .021, respectively) (Fig. 1).
Particularly, a signiﬁcant increase, after 4hours chocolate
consumption, was evidenced in plasma for compounds 1
(P= .004), 3 (P= .043), 5 (P= .035), and 6 (P= .039) (Fig. 1).
No signiﬁcant differences were observed between the sum of all
phenyl-g-valerolactone concentrations measured at T0 and T1
(0.85±1.45 vs 1.11±1.13mmol/L, P= .54, respectively) (Fig. 2).
Among phenyl-g-valerolactones, compound 7 was detected in
very few plasma samples and it was excluded from the results due
to its high inter-individual variability. A slight, but signiﬁcant
(P= .007) decrease of compound 9 has been observed at T1
compared with baseline (Fig. 2).
Collagen/ADP-induced closure time was found to be signiﬁ-
cantly increased 4hours after dark chocolate ingestion (98.5±
13.0 vs 114.5±22.0seconds, P< .001), while the closure time of
collagen/epinephrine remained unchanged (128.5±27.0 vs
122.5±34.0seconds, P= .33) (Fig. 3).
Among SREMs, the 4hours concentration increase of
compound 3 signiﬁcantly correlated with the 4hours increase
of compound 4 (rho=0.64, P= .004). Intriguingly, the increased
concentration of both compounds 3 and 4 signiﬁcantly correlated
Table 2
(Epi)catechin and phenyl-g-valerolactone metabolites detected in plasma samples.
Quantiﬁer Qualiﬁer
Id Metabolite Rt (min) Parent ion (m/z) S-lens Product ion (m/z) CE (V) Product ion (m/z) CE (V)
1 (Epi)catechin-glucuronide 3.85 465 98 289 27 245 16
2 (Epi)catechin-glucuronide-sulfate 4.01 545 98 369 18 289 27
3 (Epi)catechin-sulfate (isomer 1) 4.18 369 98 289 27 245 16
4 (Epi)catechin-sulfate (isomer 2) 4.52 369 98 289 27 245 16
5 Methyl-(epi)catechin-sulfate (isomer 1) 4.52 383 98 303 20 245 16
6 Methyl-(epi)catechin-sulfate (isomer 2) 4.79 383 98 303 20 245 16
7 5-(30-Hydroxyphenyl)-g-valerolactone-40-glucuronide 3.49 383 87 207 27 163 40
8 5-Phenyl-g-valerolactone-glucuronide-sulfate 3.60 463 87 287 27 207 40
9 5-(40-Hydroxyphenyl)-g-valerolactone-30-glucuronide 3.70 383 87 207 27 163 40
10 5-Phenyl-g-valerolactone-30-glucuronide 3.96 367 93 191 25 147 43
11 5-(Hydroxyphenyl)-g-valerolactone-sulfate isomers
∗
4.54 287 96 207 23 163 35
12 5-Phenyl-g-valerolactone-sulfate-methoxy 4.88 301 96 221 23 206 40
13 5-Phenyl-g-valerolactone-30-sulfate 4.80 271 93 191 23 106 48
CE = collision energy, Rt = retention time.
∗
This compound is the sum of two isomers coeluting, 5-(30-hydroxyphenyl)-g-valerolactone-40-sulphate and 5-(40-hydroxyphenyl)-g-valerolactone-30-sulphate.
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0.94, P< .001, respectively) (data not shown). No signiﬁcant
correlations have been found among the phenyl-g-valerolactone
delta values.
Interestingly, the increase of collagen/ADP closure time was
found to signiﬁcantly correlate with the increase of total SREMs
(rho=0.55, P= .019), as well as with compounds 3 (rho=0.62,
P= .006) and 4 (rho=0.72, P= .001) (Table 3). No signiﬁcant
correlations have been found among the phenyl-g-valerolactones
and the considered coagulation outcomes.
Age and BMI have not been found to signiﬁcantly correlate
with delta closure time of collagen/epinephrine or delta collagen/
ADP closure time values (P> .05).4. Discussion
The results of this study conﬁrm that cocoa polyphenols may
exert a favorable activity on the platelet function in healthy menFigure 1. Structurally-related (epi)catechin metabolite (SREM) concentrations
before cocoa intake (0hour) and 4hours afterwards (4hours).
∗
P< .05; 1, (epi)
catechin-glucuronide; 2, (epi)catechin-glucuronide-sulfate; 3, (epi)catechin-
sulfate (isomer 1); 4, (epi)catechin-sulfate (isomer 2); 5, methyl-(epi)catechin-
sulfate (isomer 1); 6, methyl-(epi)catechin-sulfate (isomer 2).
3subjects, especially with respect to adhesion and stable aggregate
formation. More speciﬁcally, an acute inhibitory effect of cocoa
(i.e., 14% prolongation of closure time) was observed on
adhesion and aggregation triggered by ADP/collagen, 4hours
after cocoa intake. The highly signiﬁcant correlation observed
between closure time prolongation and plasma SREMs also
suggests that this inhibitory effect may be mediated by these
compounds. Phenyl-g-valerolactone plasma concentrations were
low after 4hours cocoa intake and seemed not to have relevant
inﬂuence on platelet inhibition activity.
To the best of our knowledge, only 1 intervention study has
previously investigated the acute effect of dark chocolate
consumption on platelet function using PFA-100.[17] A signiﬁcant
increase in closure time of both ADP/collagen and EPI/collagen
was observed 2hours after chocolate consumption, while only
ADP/collagen closure time was signiﬁcantly prolonged still 6Figure 2. Phenyl-g-valerolactones (VL) concentrations before cocoa intake
(0hour) and 4hours afterwards (4hours). Legend: 7, 5-(30-hydroxyphenyl)-
g-valerolactone-40-glucuronide; 8, 5-phenyl-g-valerolactone-glucuronide-sul-
fate; 9, 5-(40-hydroxyphenyl)-g-valerolactone-30-glucuronide; 10, 5-phenyl-
g-valerolactone-30-glucuronide; 11, 5-(hydroxyphenyl)-g-valerolactone-sulfate






Figure 3. Closure time (CT) induced by collagen and adenosine-50-dipho-
sphate (COLL/ADP) and collagen/epinephrine (COLL/EPI) before cocoa intake
(0hour) and 4hours afterwards (4hours).
∗
P< .05.
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with our data and suggest that the potential inhibitory effect of
ﬂavan-3-ol metabolites on platelet function may be time-
dependent. Nevertheless, ﬂavan-3-ols, or the deriving metabo-
lites, had not been assayed in the mentioned study and no
assumptions could be made concerning the inﬂuence of
individual metabolites and the clinical outcome. The work of
Bordeaux et al,[18] where a 24-hour diet recall was administered
to evaluate the consumption of chocolate-based products,
reported a signiﬁcant increase of PFA closure time between
individuals consuming a relatively modest amount of commercial
chocolate when compared with those who abstained from
chocolate consumption. Concerning the effects of dark chocolate
long-term consumption on cardiovascular risk events, most of the
evidence of the beneﬁcial effects are inferred from epidemiologi-
cal studies,[19] as there is a lack of long-term (>18 weeks) dietaryTable 3
Spearman correlations among structurally-related (epi)catechin me
concentration increase detected in plasma samples and closure tim
1 2 3
COLL/ADP, s
Rho 0.439 0.105 0.62
P .068 .677 .006
COLL/EPI, s
Rho 0.234 0.080 0.363




Rho 0.365 0.025 0.006
P .137 .922 .981
COLL/EPI, s
Rho 0.117 0.356 0.332
P .643 .147 .178
1 indicates (epi)catechin-glucuronide; 2, (epi)catechin-glucuronide-sulfate; 3, (epi)catechin-sulfate (isom
catechin-sulfate (isomer 2); 7, 5-(30-hydroxyphenyl)-g-valerolactone-40-glucuronide; 8, 5-phenyl-g-valer
g-valerolactone-30-glucuronide; 11, 5-(hydroxyphenyl)-g-valerolactone-sulfate isomers; 12, 5-phenyl-g-
4intervention studies. In a recent study, an algorithmwas set-
up to estimate the long-term effects of dark chocolate consump-
tion in a population with metabolic syndrome at high risk of
cardiovascular disease.[22] Results showed that a daily consump-
tion of dark chocolate—at least 60% to 70% in cocoa—might
prevent 70 non-fatal cardiovascular events and 15 cardiovascu-
lar-related deaths per 10,000 population treated over 10
years.[22]
Some mechanisms were proposed to explain the putative
inhibitory effects of ﬂavonoids on platelet function. Cocoa
ﬂavanols were shown to exert antioxidant properties by directly
increasing nitric oxide (NO) bioavailability,[23] mainly through
inhibition of protein kinase C-dependent NADPH oxidase[24]
and the inhibition of the vasoconstrictor endothelin-1.[25] NO is a
potent platelet inhibitor, since it inhibits the generation of platelet
isoprostanes through NOX2 gene down-regulation,[26] thus
reducing platelet adhesion.[27] Moreover, high NO availability
was shown to inhibit platelet reactivity, by especially inhibiting
platelet aggregation,[28] secretion,[29] adhesion,[23,30] and ﬁbrin-
ogen binding to its receptor, GpIIb-IIIa.[31] Rein et al[5] also
showed that the expression of ﬁbrinogen receptor GPIIb-IIIa was
signiﬁcantly decreased in healthy individuals consuming a cocoa
beverage.
These ﬁndings provide a reasonable explanation to our data.
Reliable evidence has been provided that a NO-dependent
platelet activation is more stably inhibited when triggered by
ADP than ephinephrine in normal subjects.[32,33] Interestingly, it
has also been observed that the epinephrine-mediated activation
of ﬁbrinogen receptor GPIIb-IIIa is much lower than that
achievable with ADP in healthy subjects.[34] Therefore, the strong
ﬂavonoid-mediated NO generation and GPIIb-IIIa inhibition
probably explains why we failed to observe a stable prolongation
of collagen/epinephrine closure time on PFA-100 after dark
chocolate intake, since both these biological pathways are more
strongly targeted by ADP than by epinephrine. Notably, these
ﬁndings may be of substantial clinical signiﬁcance, since a very
recent and large longitudinal community-based cohort study
showed that platelet hyperreactivity to ADP in health subjects
free of cardiovascular disease is strongly associated with futuretabolite (SREM) or phenyl-g-valerolactone (VL) metabolite delta
e of both collagen/epinephrine and collagen/ADP.
SREMs, mM
4 5 6 Total SREMs
0.720 0.177 0.191 0.546
.001 .483 .447 .019
0.034 0.177 0.122 0.083
.893 .483 .630 .744
l-g-valerolactones, mM
11 12 13 Total VL
0.129 0.164 0.293 0.052
.610 .516 .237 .839
0.091 0.143 0.234 0.036
.720 .571 .350 .887
er 1); 4, (epi)catechin-sulfate (isomer 2); 5, methyl-(epi)catechin-sulfate (isomer 1); 6, methyl-(epi)
olactone-glucuronide-sulfate; 9, 5-(40-hydroxyphenyl)-g-valerolactone-30-glucuronide; 10, 5-phenyl-
valerolactone-sulfate-methoxy; and 13, 5-phenyl-g-valerolactone-30-sulfate.
Montagnana et al. Medicine (2018) 97:49 www.md-journal.comrisk of arterial thrombosis, while a similar association could not
be observed for platelet hyperreactivity to epinephrine.[35]
The statistically signiﬁcant positive correlation observed
between SREM plasma concentrations and ADP/collagen closure
times seems to endorse these early-absorbed ﬂavan-3-ol metab-
olites as main mediators of platelet inhibition. Furthermore,
among the SREMs, (epi)catechin-sulfate isomers have shown
higher circulating levels compared with the other (epi)catechin
metabolites and signiﬁcantly correlated with ADP/collagen
closure time delta values. Not being inﬂuenced by age or BMI,
the ADP/collagen closure time seems to be really mainly
inﬂuenced by the increase of (epi)catechin-sulfate isomers
circulating levels.
Clearly, our pilot study has several limitations, ﬁrst of which
regards the study population. As already reported, absorption,
distribution, metabolism, and elimination (ADME) of ﬂavan-3-
ols are clearly inﬂuenced by gut microbiotametabolism[3,4,36] and
a wider sample size should have been considered. Moreover, the
decision to include only healthy man volunteers in the
intervention limited the target population and the completeness
of results. On the other hand, this choice allowed to study and
discuss the potential anti-thrombotic effects of chocolate intake in
a more homogeneous group, as previous studies demonstrated
that sex speciﬁc hormones deeply inﬂuence ﬂavonoids absorption
and metabolism,[37] as well as platelet response.[38] The 4hour-
time collection point might be considered as a limitation of the
study for the quantiﬁcation of the phenyl-g-valerolactones in
plasma samples, as they are generated after interaction of ﬂavan-
3-ols with the colonic microbiota in the large intestine also more
than 4-hour after chocolate intake.[3] Additionally, as the
volunteers of this short study had not been asked to abstain
from ﬂavan-3-ol rich food sources during the days before the test,
the presence of their metabolites, at low concentrations, in their
system even at T0 was expected.[39]
Finally, the use of a singlemarkerof platelet function, namely the
PFA-100might be inﬂuenced by other changes such as hematocrit,
platelet count, and von Willebrand factor level and activity.
Although we did not measure these other components, our group
previously demonstrated that the consumption of chocolate did
not affect those parameters.[13,40] We also did not undertake
serial time-course collections to interrogate time-course effects.
However, this can form the basis of a subsequent study.
In conclusion, due to the essential role played by platelets in the
pathophysiology of both arterial and venous thrombosis,[41] we
may conclude that dark chocolate consumption may be beneﬁcial
for subjects at increased risk of thrombosis and that its action
may be mediated by the appearance of SREMs into systemic
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